

# Oxidative Damage Compromises Energy Metabolism in the Axonal Degeneration Mouse Model of X-Adrenoleukodystrophy

Jorge Galino,<sup>1,2</sup> Montserrat Ruiz,<sup>1,2,\*</sup> Stéphane Fourcade,<sup>1,2,\*</sup> Agatha Schlüter,<sup>1,2</sup> Jone López-Erauskin,<sup>1,2</sup> Cristina Guilera,<sup>1,2</sup> Mariona Jove,<sup>3</sup> Alba Naudi,<sup>3</sup> Elena García-Arumí,<sup>2,4</sup> Antoni L. Andreu,<sup>2,4</sup> Anatoly A. Starkov,<sup>5</sup> Reinald Pamplona,<sup>3</sup> Isidre Ferrer,<sup>6,7</sup> Manuel Portero-Otin,<sup>3</sup> and Aurora Pujol<sup>1,2,6,8</sup>

## Abstract

**Aims:** Chronic metabolic impairment and oxidative stress are associated with the pathogenesis of axonal dysfunction in a growing number of neurodegenerative conditions. To investigate the intertwining of both noxious factors, we have chosen the mouse model of adrenoleukodystrophy (X-ALD), which exhibits axonal degeneration in spinal cords and motor disability. The disease is caused by loss of function of the ABCD1 transporter, involved in the import and degradation of very long-chain fatty acids (VLCFA) in peroxisomes. Oxidative stress due to VLCFA excess appears early in the neurodegenerative cascade. **Results:** In this study, we demonstrate by redox proteomics that oxidative damage to proteins specifically affects five key enzymes of glycolysis and TCA (Tricarboxylic acid) cycle in spinal cords of *Abcd1*<sup>-</sup> mice and pyruvate kinase in human X-ALD fibroblasts. We also show that NADH and ATP levels are significantly diminished in these samples, together with decrease of pyruvate kinase activities and GSH levels, and increase of NADPH. **Innovation:** Treating *Abcd1*<sup>-</sup> mice with the antioxidants N-acetylcysteine and  $\alpha$ -lipoic acid (LA) prevents protein oxidation; preserves NADH, NADPH, ATP, and GSH levels; and normalizes pyruvate kinase activity, which implies that oxidative stress provoked by VLCFA results in bioenergetic dysfunction, at a presymptomatic stage. **Conclusion:** Our results provide mechanistic insight into the beneficial effects of antioxidants and enhance the rationale for translation into clinical trials for X-adrenoleukodystrophy. *Antioxid. Redox Signal.* 15, 2095–2107.

## Introduction

**I**MPAIRED BIOENERGETICS and mitochondria metabolism, together with oxidative stress, are commonalities underlying age-related neurodegenerative diseases, such as Parkinson's (PD), Huntington's (HD) and Alzheimer's (AD) disease, Friedreich's ataxia, or amyotrophic lateral sclerosis (ALS), to cite a few (11, 12, 14, 29, 36, 37, 40). It has been postulated that oxidative stress in mitochondria can reduce the activities of their various proteins due to oxidative modifications (8, 32, 43, 60, 65). Oxidative stress can also provoke mutations in the mtDNA, which is more sensitive than nuclear DNA to reactive

oxygen species (ROS) (45). Both mtDNA and protein modifications may result in a metabolic failure characterized by an increase in NAD<sup>+</sup>/NADH ratio (*i.e.*, a decrease in cellular reducing potential), which is a powerful regulator of glycolysis, TCA cycle, and oxidative phosphorylation (69) and also in reduced levels of ATP (16, 23).

Here we sought to investigate energy homeostasis in a model of axonal degeneration caused by oxidative stress of a known etiology, the mouse model of X-linked adrenoleukodystrophy (X-ALD; McKusick no. 300100). This is a rare and fatal disease characterized by central inflammatory demyelination in the brain or slowly progressive spastic paraparesis,

<sup>1</sup>Neurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.

<sup>2</sup>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, Spain.

<sup>3</sup>Departament de Medicina Experimental, Universitat de Lleida-IRB LLEIDA, Lleida, Spain.

<sup>4</sup>Unitat de Patologia Mitocondrial, Centre d'Investigacions en Bioquímica i Biologia Molecular, Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain.

<sup>5</sup>Department of Neurology, Weill Cornell Medical Center, New York, New York.

<sup>6</sup>Institut de Neuropatologia, Hospital Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain.

<sup>7</sup>CIBERNED, ISCIII, Barcelona, Spain.

<sup>8</sup>Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain.

\*These authors contributed equally to this work.

as a consequence of axonal degeneration in the spinal cord (17, 42). X-ALD is the most frequently inherited leukodystrophy, with a minimum incidence of 1 in 17,000 men. All patients have mutations in the gene encoding the ABCD1 protein (NM\_000033), an ATP binding cassette peroxisomal transporter involved in the importing of very long-chain fatty acids (VLCFA, C  $\geq$  22:0) and VLCFA-CoA esters into the peroxisome for degradation (66). Defective function of the ABCD1 transporter leads to VLCFA accumulation in most organs and plasma; and elevated levels of VLCFA are used as a biomarker for the biochemical diagnosis of the disease. Classical inactivation of ABCD1 in the mouse results in late onset neurodegeneration with axonopathy in spinal cord, in the absence of inflammatory demyelination in the brain, resembling the most frequent X-ALD phenotype or adrenomyeloneuropathy (49, 50). Oxidative damage has been evidenced in postmortem brain samples from individuals with cerebral ALD (24) and in mouse spinal cords before disease onset (20). Further, we recently reported compelling evidence that a combination of antioxidants halts clinical progression and reverses axonal damage in X-ALD mouse model, thereby providing formal conceptual proof that oxidative injury is a major etiopathogenic factor in this disease (38). The source of this oxidative damage is most likely an excess of saturated and unsaturated VLCFA, which are known to generate free radicals and cause oxidative damage to proteins in cell culture (20, 22).


In this study, we demonstrate by a redox proteomics approach that ABCD1 ablation induces the oxidation of enzymes of glycolysis and TCA cycle in spinal cords. This oxidation inactivates the affected enzymes, and bioenergetic failure is manifested by decreased levels of cellular NADH and ATP, together with decreased levels of GSH. All these changes occur months before disease onset. Additionally, we provide evidence that the combination of antioxidants N-acetylcysteine and  $\alpha$ -lipoic acid prevents protein oxidation and metabolic failure in spinal cords.

## Results

### *ABCD1 loss induces the specific oxidation of glycolysis and tricarboxylic acid cycle enzymes in spinal cord*

We pointed out earlier that oxidative damage is a main etiopathogenic factor in X-ALD mouse model (20, 38). This damage is characterized by an increase in the markers of lipoxidation to proteins (MDA-lysine), combined with markers of glycooxidation and lipoxidation, carboxyethyl-lysine (CEL) and carboxymethyl-lysine (CML), together with markers of direct carbonylation of proteins (glutamic semialdehyde [GSA] and amino adipic semialdehyde [AASA]), in spinal cords and in peripheral mononuclear cells or fibroblasts derived from patients with X-ALD (20, 22). Thus, we set out to identify oxidation targets in spinal cords with a redox proteomics approach (54).

Using this methodology (Fig. 1A and Supplementary Table S1; Supplementary Data are available online at [www.liebertonline.com/ars](http://www.liebertonline.com/ars)), five oxidized proteins were pinpointed: aldolase A (ALDO A), phosphoglycerate kinase (PGK1), pyruvate kinase (PKM2), dihydrolipoamide dehydrogenase (DLD), and mitochondrial aconitase (ACO2). To confirm that the excised spot corresponded to the five identified proteins, we performed a 2D gel, then a western blot with an antibody against each specific protein, with the same sam-



**FIG. 1.** ALDO A, PGK1, PKM2, DLD, and ACO2 are more highly oxidized in spinal cord from 12 month-old *Abcd1*<sup>-/-</sup> mice. (A) Redox proteomics experiments in Wt and *Abcd1*<sup>-/-</sup> mice. Western blot with an antibody anti-DNP was performed to identify oxidized proteins ( $n=5$ /genotype). A validation Western blot was performed with specific antibodies against aldolase A (ALDO A), phosphoglycerate kinase (PGK1), pyruvate kinase (PKM2), dihydrolipoamide dehydrogenase (DLD), and mitochondrial aconitase (ACO2) after identification obtained by MS (B), allowing relative quantification of their expression (C). Relative protein level is expressed as a percentage of control, and referred to  $\gamma$ -tubulin as loading marker. (D) *Pkm2* was quantified by Q-PCR in Wt and *Abcd1*<sup>-/-</sup> mice. *36b4* was used as internal control ( $n=10$ –12 by genotype). Statistical analysis was done by Student's *t*-test: \* $p < 0.05$ .

ples that were used in Figure 1A, both wild type and *Abcd1*<sup>-/-</sup>. Results are shown for the *Abcd1*<sup>-/-</sup> membrane (Fig. 1B). We also quantified mRNA and protein expression levels and found that pyruvate kinase is repressed in 12 month-old *Abcd1*<sup>-/-</sup> spinal cord (Fig. 1C, D). The expression of the four other oxidized proteins was not modified in *Abcd1*<sup>-/-</sup> mice (Fig. 1C).

#### C26:0 excess induces pyruvate kinase oxidative inactivation in human fibroblasts

Earlier, we reported that the levels of lipoxidative (MDAL), glycoxidative/lipoxidative (CEL, CML), and protein oxidative (GSA; AASA) markers were about doubled in the fibroblasts derived from patients with X-ALD (20). We also demonstrated that excess C26:0 generates ROS in human fibroblasts (20) and oxidative lesions to proteins in X-ALD fibroblasts. To identify which proteins are oxidation targets in human X-ALD fibroblasts, we performed redox proteomics. We found that PKM2 is more oxidized in human X-ALD than in control fibroblasts (Fig. 2A). To investigate whether C26:0 excess is involved in the PKM2 oxidation, we also performed redox proteomics experiments with cultured human nondiseased and X-ALD fibroblasts that were treated with a pathophysiologically relevant dose of C26:0 (100  $\mu$ M) for 7 days, as previously described (20). We found that C26:0 excess induces PKM2 oxidation and inactivation in both nondiseased and X-ALD fibroblasts (Fig. 2A). As control, we incubated X-ALD and nondiseased fibroblasts with 100  $\mu$ M oleic acid (C18:1) and could not detect ox-


idation increases in 2D gels after DNP exposure (data not shown). No signs of toxicity or reduced proliferation were seen in the cultures. To confirm that the excised spot corresponded to PKM2, we also performed a 2D gel, then a western blot with an antibody against PKM2 (Fig. 2B and Supplementary Table S1). Further, we quantified *PKM2* gene expression and found that it was neither affected by genotype nor by C26:0 excess in human fibroblasts (Fig. 2C).

#### ABCD1 loss provokes specific glycolytic and TCA cycle metabolic signature in spinal cord


Several reports indicate that oxidation of enzymes involved in energy metabolism results in a decrease in their activity (8, 60, 65). To investigate whether enzyme activity is affected in our model, we quantified substrates and/or products of the five oxidized enzymes with a directed metabolomics approach.

We found that the level of fructose 1,6-bisphosphate, the substrate of ALDO A, was not modified in *Abcd1*<sup>-/-</sup> spinal cord (Fig. 3A and Table 1). However, its products—dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (GA3P)—were present at significantly lower levels in *Abcd1*<sup>-/-</sup> mice, which suggests that oxidation affected ALDO A activity *in vivo* (Fig. 3A and Table 1). Lower levels of DHAP and GA3P could also be explained by its nonenzymatic conversion to methylglyoxate (MGO) (48), which can be degraded through glyoxalases and/or react with lysine residues in proteins. This is consistent with the reported increase in carboxyethyllysine

**FIG. 2. PKM2 is oxidized by C26:0 excess in human fibroblasts.** (A) Redox proteomics experiments were performed in human control and X-ALD fibroblasts ( $n=5$  per genotype and condition), which were treated for 7 days with BSA-conjugated C26:0 (100  $\mu$ M) or BSA as control in a serum-free medium. Western blot with an antibody anti-DNP was performed to identify oxidized proteins. Western blot was performed with a specific antibody against pyruvate kinase (PKM2) to validate the protein identification obtained by MS (B) or to quantify their expression (C). Relative protein level is expressed as a percentage of control, and referred to  $\gamma$ -tubulin as loading marker. Significant differences were revealed by ANOVA followed by Tukey HSD *post hoc* test.







**FIG. 3. Metabolite levels in 12 month-old spinal cord from *Abcd1*-deficient mice.** (A) Fructose 1–6 bisphosphate, dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3 phosphate (GA3P), 2 and 3-phosphoglycerate, pyruvate, lactate, oxaloacetate, citrate,  $\alpha$ -ketoglutarate, fumarate, and malate levels in Wt and *Abcd1*<sup>-</sup> mice. (B) Pyruvate/lactate ratio is not modified in *Abcd1*<sup>-</sup> spinal cord at 12m of age. (C) Pyruvate kinase activity is decreased in 12 month *Abcd1*-null mice spinal cord. Pyruvate kinase activity is expressed as units/mg tissue ( $n=5-7$ /genotype). Statistical analysis was done with Student's t-test (\* $p \leq 0.05$ , \*\* $p \leq 0.01$ , and \*\*\* $p \leq 0.001$ ).

(CEL) (20). 2-Phosphoglycerate and 3-Phosphoglycerate cannot be distinguished by MS, but an  $m/z$  (mass-to-charge ratio) ion compatible with their masses is lowered in spinal cord from *Abcd1*<sup>-</sup> mice, which suggests that activities of PGK1 (which produces 3-Phosphoglycerate) and/or Phosphoglycerate mutase (which converts 3-Phosphoglycerate into 2-Phosphoglycerate) were modified (Fig. 3A). Since PGK1 was found to be oxidized in our model, 3-Phosphoglycerate level was likely decreased due to lower PGK1 activity (Fig. 3A).

Dihydrolipoamide dehydrogenase (DLD), a subunit of  $\alpha$ -ketoglutarate dehydrogenase complex (KGDHC) and of four other important mitochondrial enzymes, was found to be oxidized, and the concentration of its substrate  $\alpha$ -ketoglutarate was increased in *Abcd1*<sup>-</sup> spinal cord (Fig. 3A). Thus, we hypothesized that KGDHC activity was most likely to be decreased in *Abcd1*-null mice, even if the steady-state level of  $\alpha$ -ketoglutarate is also determined by several factors such as glutamate availability and the rate-limiting enzyme in KGDHC is not DLD but  $\alpha$ -ketoglutarate dehydrogenase E1k.

Since DLD is also a subcomponent of pyruvate dehydrogenase complex (PDHC), it was expected that pyruvate catabolism would also be altered. However, we found that pyruvate level was not modified in *Abcd1*-null spinal cord. Although lactate level and the pyruvate/lactate ratio are not modified in *Abcd1*<sup>-</sup> spinal cord, we found that PKM2 was oxidized and its expression decreased in *Abcd1*<sup>-</sup> spinal cord (Fig. 3A, B). These

results indicate that steady-state level of pyruvate is maintained through a balanced decrease in its synthesis and degradation, without lactate accumulation. This could be due, for instance, to concerted decreased glycolytic production of pyruvate and its decreased uptake or oxidation in mitochondria.

We also found that citrate concentration was increased in spinal cord from *Abcd1*-null mice, which suggests a defect in citrate catabolism (Fig. 3A), likely due to the oxidative damage to ACO2 in *Abcd1*<sup>-</sup> mice (Fig. 3A).

Moreover, we also observed that (i) oxaloacetate (OAA), fumarate, and malate levels are not affected and (ii) the enzymes involved in the production or degradation of these metabolites are not oxidized.

Altogether, these results demonstrate for the first time pronounced bioenergetic dysfunction in spinal cord from *Abcd1*-null mice, at presymptomatic stages (Fig. 3A).

#### *ABCD1* loss decreases pyruvate kinase activity in spinal cord

The results just shown suggest that the pyruvate steady-state level is not modified by *ABCD1* loss, because its synthesis and catabolism may be reduced. In addition, we demonstrated that pyruvate kinase (PKM2) was highly oxidized and its expression reduced in spinal cord from *Abcd1*<sup>-</sup> mice (Fig. 3C). To investigate whether pyruvate synthesis was affected, we assessed the activity of pyruvate kinase and found that it was decreased in spinal cord from 12 month-old *Abcd1*<sup>-</sup> mice (Fig. 3C). No significant dysregulation of pyruvate kinase activity was found in 12 month-old mouse brain cortex or liver and in spinal cords at an earlier stage (3 months) (Supplementary Fig. S1).

#### *ABCD1* loss disturbs NADH, NADPH, GSH, and ATP levels in spinal cord

To study possible global consequences of protein oxidation on energy homeostasis, we quantified NAD<sup>+</sup>, NADH, NADP<sup>+</sup>, NADPH, and ATP contents (60, 65) in *Abcd1*<sup>-</sup> spinal cords at 12 months. NADH but not NAD<sup>+</sup> levels were reduced on *ABCD1* loss compared with Wt samples (Fig. 4A). Consequently, the NAD<sup>+</sup>/NADH ratio was increased (Fig. 4A), thus reflecting an abnormal redox status. Moreover, we observed that NADPH was elevated in *Abcd1*<sup>-</sup> spinal cords at 12 months (Fig. 4B). The levels of reduced glutathione (GSH) are intimately related to NADPH, because the GSH/GSSG ratio is determined by the NADPH consuming enzyme Glutathione Reductase (GR) (31, 69). We have, therefore, quantified GSH levels in whole spinal cord extracts, to find out that GSH levels were reduced in *Abcd1*<sup>-</sup> mice, a situation consistent with increased oxidative stress (Fig. 4C). In addition, we found that ATP is also reduced in these samples (Fig. 4D), which directly indicates bioenergetic failure. However, NAD<sup>+</sup>, NADH, and ATP levels were not affected in brain cortex or liver at 12 month of age or in spinal cord at 3 months of age in *Abcd1*-null mice, indicating organ specificity and progressive nature of the metabolic impairment (Supplementary Fig. S2). Altogether, these results point out the specific importance of *ABCD1* in the energy metabolism of the spinal cord of aged, but still presymptomatic, *Abcd1*<sup>-</sup> mice.

To investigate whether the decrease of ATP could be due to mitochondrial respiratory chain impairment, we measured the activity of respiratory chain complexes in spinal cords

TABLE 1. METABOLITE LEVELS IN 12 MONTH-OLD SPINAL CORD FROM *Abcd1*<sup>-</sup> MICE

Metabolite	Enzymes	Values (mean ± SD)	Fold change (Wt vs. <i>Abcd1</i> <sup>-</sup> )	p-Value
Fructose 1,6 biphosphate	Aldolase <sup>a</sup>	Wt=52776 ± 16221 <i>Abcd1</i> <sup>-</sup> = 47710 ± 8971	-10%	n.s.
DHAP/GA3P	Aldolase <sup>a</sup>	Wt=178258 ± 87111 <i>Abcd1</i> <sup>-</sup> = 74938 ± 44601	-58%	<0.05
2(or 3)-phosphoglycerate	Phosphoglycerate kinase <sup>a</sup>	Wt=11533 ± 4149 <i>Abcd1</i> <sup>-</sup> = 5658 ± 1460	-51%	=0.01
Pyruvate	Pyruvate kinase <sup>a</sup> Dihydrolipoamide dehydrogenase <sup>a</sup> (Pyruvate dehydrogenase complex)	Wt=403616 ± 132627 <i>Abcd1</i> <sup>-</sup> = 462663 ± 69665	+14%	n.s.
Lactate	Lactate dehydrogenase	Wt=6253 ± 583 <i>Abcd1</i> <sup>-</sup> = 6742 ± 539	+8%	n.s.
Oxaloacetate	Citrate synthase	Wt=11160 ± 3668 <i>Abcd1</i> <sup>-</sup> = 11689 ± 3076	+4%	n.s.
Citrate	Aconitase <sup>a</sup>	Wt=6592 ± 1799 <i>Abcd1</i> <sup>-</sup> = 9747 ± 1724	+47%	=0.02
α-Ketoglutarate	Dihydrolipoamide dehydrogenase <sup>a</sup> (α-ketoglutarate dehydrogenase complex)	Wt=76446 ± 3633 <i>Abcd1</i> <sup>-</sup> = 92223 ± 10805	+20%	=0.01
Fumarate	Fumarase	Wt=16860 ± 2531 <i>Abcd1</i> <sup>-</sup> = 18587 ± 5114	+10%	n.s.
Malate	Malate dehydrogenase	Wt=70599 ± 11146 <i>Abcd1</i> <sup>-</sup> = 64810 ± 17845	-8%	n.s.

Fructose 1–6 biphosphate, dihydroxyacetone phosphate and glyceraldehyde 3 phosphate (GA3P), 2 and 3-phosphoglycerate, pyruvate, lactate, oxaloacetate, citrate, α-ketoglutarate, fumarate, and malate levels were quantified in Wt and *Abcd1*<sup>-</sup> mice.

<sup>a</sup>Oxidized.

n.s. not significant.

extracts from 12 month-old *Abcd1*<sup>-</sup> mice. We quantified the activities of complex I plus complex III, complex II plus complex III and complex IV. Activities did not vary between *Abcd1*-null and wild type littermates (Supplementary Fig. S3).

#### A combination of antioxidants prevents oxidative stress and metabolic failure

We have previously shown that a cocktail of antioxidants including N-acetylcysteine (NAC), α-lipoic acid (LA), and vitamin E reversed oxidative damage to proteins and DNA, immunohistological signs of axonal degeneration and associated locomotor disability in an X-ALD mouse model (38).

To investigate whether these antioxidants were effective in counteracting oxidative stress to the specific proteins identified, we treated 8 month-old *Abcd1*<sup>-</sup> mice with a combination of NAC and LA for 4 months. We have previously reported that excess of VLCFA decreases reduced glutathione, and X-ALD cells are more sensitive to glutathione depletion (20). N-acetylcysteine was chosen, because it can regenerate reduced glutathione (GSH) and scavenge several ROS species including OH<sup>•</sup>, H<sub>2</sub>O<sub>2</sub>, peroxy radicals, and nitrogen-centered free radical (28). α-lipoic acid (LA) was chosen, as it can regenerate GSH from its oxidized counterpart (GS-SG) (3), thus enhancing the effects of NAC. LA and its reduced form, dihydrolipoic acid, may use their chemical properties as a redox couple to alter protein conformations by forming mixed disulfides, thus protecting proteins from oxidation. Redox proteomics revealed that the antioxidant treatment prevented selective oxidation of ALDOA, PGK1, PKM2, DLD, and ACO2 (Fig. 5A, B).

We also observed that the *Abcd1*-associated loss of pyruvate kinase activity and expression was prevented by NAC and LA, thereby suggesting that *in vivo*, the level of oxidation of this protein may directly correlate with its expression and enzymatic activity (Fig. 5C, D).

The reduction of NADH, GSH, and ATP levels and the increase of NADPH were all prevented by antioxidants





FIG. 4. *ABCD1* loss disturbs NADH, NADPH, GSH, and ATP levels in spinal cord from 12 month-old *Abcd1*-null mice. (A) NADH, NAD<sup>+</sup> levels and NAD<sup>+</sup>/NADH ratio, (B) NADPH, NADP<sup>+</sup> levels and NADP<sup>+</sup>/NADPH, (C) GSH levels, and (D) ATP levels in Wt and *Abcd1*-null mice (*n*=8/genotype). Statistical analysis was done with Student's *t*-test: \**p*<0.05, \*\**p*<0.01, \*\*\**p*<0.001.



**FIG. 5. Metabolic failure is prevented by a combination of antioxidants.** (A) Redox proteomics experiments were performed in 12 month-old *Abcd1*<sup>-</sup> and *Abcd1*<sup>-</sup> mice fed for 4 months (*Abcd1*<sup>-</sup> + Antx) with NAC and LA. Western blot with an antibody anti-DNP was performed to identify oxidized proteins ( $n=5$ /genotype). (B) Western blot ( $n=4$ /genotype) against aldolase A (ALDO A), phosphoglycerate kinase (PGK1), pyruvate kinase (PKM2), dihydrolipoamide dehydrogenase (DLD), and mitochondrial aconitase (ACO2). Pyruvate kinase expression (C) and activity (D), NADH, NAD<sup>+</sup> levels and the NAD<sup>+</sup>/NADH ratio (E), NADPH, NADP<sup>+</sup> levels and NADP<sup>+</sup>/NADPH ratio (F), GSH levels, (G) and ATP levels (H) were measured in spinal cord from 12 month-old Wt, *Abcd1*<sup>-</sup> and *Abcd1*<sup>-</sup> mice fed for 4 months with a cocktail of antioxidants (*Abcd1*<sup>-</sup> + Antx) ( $n=6-7$  mice per genotype and condition). Statistical analysis was done with ANOVA followed by Tukey HSD *post hoc* test. Significant differences are shown as \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$ .

(Fig. 5E-H), indicating that the treatment was effective in preventing bioenergetic failure.

## Discussion

We have previously suggested that oxidative damage could be a significant factor contributing to X-ALD pathogenesis (20, 38, 58). This study corroborates our hypothesis

and points to how energetic failure manifested by diminished levels of NADH and ATP is most likely due to inhibition of glycolysis and TCA cycle resulting from the early oxidative damage to proteins. Further, our findings strongly suggest that energetic failure plays a major role in the physiopathogenesis of X-ALD, because (i) is progressive and appears presymptomatically at 12 months of age, in a mouse that exhibits first locomotor disabilities at 20–22 months of age; (ii)




*in vivo* antioxidant treatment prevented motor disability and axonal degeneration (38), and also oxidative damage of important glycolytic and TCA cycle proteins normalizing NADH, NADPH, GSH, and ATP levels (Fig. 6).

It has been suggested that oxidative modification of key mitochondrial TCA enzymes such as pyruvate and  $\alpha$ -ketoglutarate dehydrogenases and aconitase may be an important pathophysiological factor in neurodegenerative diseases, by causing mitochondria dysfunction and bioenergetic failure (8, 32, 43, 60, 65). Indeed, aconitase and KGDHC are known targets and sources of ROS and their enzymatic activity is impaired by ROS-induced oxidation (8, 32, 43, 60, 65). Further, increased mitochondrial ROS generation is thought to induce and stimulate pathogenic feedback cycle by inactivating sensitive TCA enzymes and impairing NADH and NADPH generation, which, in turn, results in further impairment of mitochondrial ROS defense capacity, disturbed  $Ca^{2+}$ , and ion homeostasis, eventually causing a decrease in ATP production and overall bioenergetic failure (43, 64, 65).

Of note, we have demonstrated that activities of respiratory chain are not modified; NADH and ATP levels are lowered and NADPH is elevated in X-ALD, *in vivo* in mouse spinal cord extracts. This tissue contains a mixture of gray and white matter, where neurons represent ~10% of the total amount of cells, whereas glia is about 90%, with astrocytes being the most abundant cell type. Energy is mainly produced by mitochondria in neurons, whereas in astrocytes most of ATP is generated by glycolysis (30). It was reported that, in the gray

matter of the brain, astrocytes export lactate (derived from glucose or glycogen) to neurons to power their mitochondria. In the white matter, lactate can support axonal function under conditions of energy deprivation (53). We, therefore, cannot exclude the possibility that the results reflect only a sum of effects in whole tissue and do not reflect a specific disturbance of a given metabolite or pathway in a particular cell type. For instance, OXPHOS activities could be impaired in, that is, neurons. Nevertheless, these results suggest that metabolic failure is most likely due to impairment in glycolysis and/or TCA cycle rather than due to damaged mitochondrial respiratory chain. In astrocytes, ATP reduction is probably due to a defective glycolysis. In neurons, the decrease in ATP levels could be due to a reduction in NADH generation in mitochondria caused by the damage to KGDHC and aconitase and/or some other unidentified catabolic enzymes. In addition, the elevation of NADPH could have been caused by an increased production *via* Pentose Phosphate Pathway (30) and/or by an inhibition of Glutathione Reductase (GR) (70). Indeed, it has been reported that the low glycolytic rate in neurons results in increased flux through the pentose-phosphate pathway, thus providing NADPH necessary to regenerate antioxidant glutathione (30).

The GSH reduction observed, and its recovery on antioxidant treatment, is in line with a major role of GSH in oxidative stress scenarios, and consistent with previous results: (i) we formerly showed that X-ALD cells were more sensitive to GSH depletion and more prone to undergo cell death due to



**FIG. 6. Working hypothesis on the interplay between metabolic failure and oxidative stress in X-ALD.** C26:0 excess generates ROS, which results in oxidation of enzymes belonging to glycolysis and TCA cycle. This oxidative damage provokes a reduction in enzyme activities, which is demonstrated by alteration of the substrate and/or product concentrations of these enzymes. An impairment of TCA leads to a reduction in NADH level, the substrate of complex I of the mitochondria respiratory chain, contributing to decreased production of ATP. This ignites a vicious circle increasing ROS production. Then, the inhibition of complex I leads to a reduction in ATP production by the mitochondria respiratory chain. Combination of NAC and LA prevent metabolic failure by protecting key enzymes of TCA and glycolysis from oxidation. Further, lipoic acid might ameliorate the function of KGDHC and PDHC.

the oxidative stress-induced damage than the passage-matched control fibroblasts (20); (ii) Glutathione peroxidase (GPX1) protein expression was increased in *Abcd1*<sup>-</sup> spinal cord (20, 38) and normalized by antioxidant treatment (38). Therefore, GSH reduction is most likely to be caused by an increased consumption by GPX1 due to an ongoing oxidative stress process in *Abcd1* spinal cords. Oxidative stress has been classically considered a common event in the neurodegenerative cascade in a variety of conditions (37, 40). Ample evidence demonstrates that energy metabolism also plays a major role in cell death (16, 23). Glycolytic and TCA cycle proteins such as ALDO A, PGK1, PKM2, DLD, and ACO2 can be considered as classical targets of oxidative stress, because the oxidation of these proteins is commonly detected in several neurodegenerative disorders (9, 40, 47, 59), although no "oxidation prone consensus" has yet been identified. ALDO A is oxidized in Parkinson mouse model (59), in amnesic mild cognitive impairment (MCI), in early onset Alzheimer disease (EOAD), and in Alzheimer (AD) human brain (9, 40). Oxidized ALDO A has also been detected in progressive supranuclear palsy (PSP) and infantile Parkinson disease (iPD) (40). PGK1 is oxidized in AD and PD mouse model (59), in MCI brain (9), and in PSP (40). Moreover, PKM2 is oxidized in MCI (9) and in Alzheimer brains (9, 40), and a correlation has been observed between levels of oxidation and activity of PKM2 in MCI brain (10), and in a rat hepatoma cellular model (27). In agreement with this observation, we demonstrate here that PKM2 is oxidized and its activity decreased in *Abcd1*-null mice. Nevertheless, as PKM2 expression is also decreased in our samples, we cannot determine whether this reduction in activity is due to oxidative stress or PKM2 protein levels. Unfortunately, no information on PKM2 expression is available in patients with MCI or patients with Alzheimer (9, 10, 40), but our result suggest that its expression levels would be worth checking. The mechanisms by which reduction in expression of PKM2 occur deserve further investigation. The decrease in ATP levels that we are reporting in this study is likely due to a mitochondria dysfunction. Indeed, ATP is mainly produced by mitochondria in nonproliferating, post-mitotic cells; whereas it is preferentially generated by glycolysis in proliferating, for example, cancer cells (19). Evidence of ultrastructural anomalies of mitochondria in spinal neurons of *Abcd1*<sup>-</sup> mice have been reported (18); this is consistent with previous findings of mitochondria alterations in liver of peroxisomal deficient models (5). According to the findings in a mouse model of AD, glycolysis induction could be a mechanism to compensate for mitochondria dysfunction as a metabolic reprogramming (68). However, this reprogramming cannot be efficient in *Abcd1*<sup>-</sup> spinal cord, because ALDO A, PFK1, and PKM2 are oxidized and their activity might be altered. It was also reported that aconitase is oxidized in both PD and AD mouse models (59), in AD (9), and in Huntington's disease (40). Further, the oxidation of DLD had been shown in two PD mouse models (59). Although some specific oxidized proteins have been identified in neurodegenerative disorders, a large number of oxidized proteins are more commonly found (9, 40, 59). This could be due to limitations of proteomics experiments. Indeed, only proteins that are very well expressed can be identified by 2D gel proteomics (56). Indeed, the Western-blot anti-DNP detect as little as 1 pmol carbonyl in a protein sample and require a minimum of as little as 50 ng protein oxidized to the extent of 0.5 mol car-

bonyl/mol protein. Moreover, intrinsic limitations to 2D gels techniques include, for instance, that proteins migrating outside a pH scale from 3 to 11 and having a molecular weight outside the range of 25–100 kD cannot be detected. Similarly, membrane-located or highly hydrophobic proteins cannot be resolved by this technique. Low-abundance proteins cannot be identified due to lowered sensitivity of MALDI-TOF sequencing. Moreover, many of these proteins are generally considered as house-keeping agents, having an essential function in maintenance of cell viability. In addition, in the case of neurons, for instance, it was shown that oxidative injury affects a large number of substrates including enzymes of the glycolysis and TCA cycle, thus resulting in a weakened energy metabolism (23). As a result, reduced ATP production in affected neurons reduces their capacity to respond to physiological energy demands such as synaptic input or axonal transport, which might lead to axonal degeneration in our particular disease scenario, or to progressive neuronal dysfunction in the most frequent neurodegenerative diseases (16).

Ample evidence indicates that oxidative damage to proteins related to energy metabolism is accompanied by the corresponding detriment of their function and impaired bioenergetics as observed in Alzheimer's and Parkinson's diseases (9, 16, 40, 59). Most commonly, this failure is manifested by a decrease in cellular ATP, as in AD (52), PD (25), and ALS (7). Less evidence is available about NADH levels. A significant decrease in both reduced and oxidized forms of NAD and an increase in NAD<sup>+</sup>/NADH ratio was reported in the brains of Ataxia-telangiectasia mouse model (61). It was also shown that oxidative products generated by dopamine were able to reduce NADH levels in isolated mitochondria (6). Both NADH and NADPH levels were decreased in neurons cultured from aged (24 month-old) rats (46). Moreover, it was shown that H<sub>2</sub>O<sub>2</sub> decreased NADH levels in nerve terminals (64) and increased NAD<sup>+</sup>/NADH ratio in neonatal heart muscle cells (33), but their ratios have not been systematically measured in most prevalent neurodegenerative diseases.

The widely used antioxidants LA and NAC have been shown to increase the level of GSH and affect the regulation of various redox signalling pathway in cells (15, 44). Combined antioxidant therapy aims at reproducing the multistep, combined response, which is observed *in vivo* leading to recovery after an oxidative challenge (35). Some studies have shown that combinations of antioxidants can be beneficial for pathologies associated with increased oxidative stress (55) and that such a strategy might be advantageous over higher doses of single antioxidants for treating mitochondriopathies (62, 63), reproducing what it is already present in nature; that is, a combination of antioxidant systems rather than a single one. In particular, it has been recently demonstrated that several combinations of antioxidants {[LA, NAC and vitamin E (4)], [LA and NAC (41)], or [LA and acetyl-L-carnitine (1, 57)]} are able to prevent oxidative damage and improve mitochondrial ultrastructural decay or dysfunction in Alzheimer disease mouse models (57), and even in some clinical studies (13, 51). Further, since LA is an essential cofactor of PDHC and KGDHC, its supplementation could protect and increase the enzymatic activity of KGDHC (2), and, therefore, help bring about an increase in NADH and ATP production. Indeed, we demonstrate in this study that the improvement in disability and axonal degeneration in X-ALD mice by LA and NAC as shown elsewhere (38) correlates with a decrease in oxidation



damage of key proteins involved in metabolic homeostasis, and with preserved NADH and ATP levels. Thus, our results provide new insights into the molecular mechanisms of action of antioxidants in X-ALD.

Moreover, we have identified new markers of pathology in the *Abcd1*<sup>-</sup> mice such as PKM2 expression level and activity, NADH, and ATP levels. These markers may become very useful to monitor the efficiency of treatments in preclinical trials in X-ALD mice. Monitoring of the biological effects of the drugs in patients would be further facilitated by the recent identification by MS/MS of quantitative biomarkers of oxidative damage to proteins in the peripheral blood mononuclear cells from patients with X-ALD (22). Therapeutic implications derived from this work could be extrapolated to other diseases in which energy metabolic failure due to oxidative stress is a main or early contributing pathogenic factor.

## Materials and Methods

### Antibodies

The following antibodies were used for western blots: anti-rabbit DNP (D9659, [Sigma]), dilution 1/500; anti-mouse  $\gamma$ -tubulin, dilution: 1/5000 (T6557, clone GTU-88 [Sigma]); anti-rabbit pyruvate kinase, dilution 1/500 (ab-38237 [Abcam]); anti-rabbit aldolase, dilution 1/1000 (NB600-915 [Novus Biologicals]); anti-rabbit-phosphoglycerate kinase 1, dilution 1/250 (AB38007 [Abcam]); anti-rabbit aconitase 2, dilution 1/1000 (ACO2-AP1936c [Abgent]); and anti-rabbit lipoamide dehydrogenase, dilution 1/1000 (L2498-05 [US Biological]). Goat anti-rabbit IgG linked to horseradish peroxidase, dilution: 1/15000 (P0448 [Dako]) and Goat anti-mouse IgG linked to horseradish peroxidase, dilution: 1/15000 (G21040 [Invitrogen]) were used as secondary antibodies.

### Mouse breeding

The generation and genotyping of *Abcd1*<sup>-</sup> mice has previously been described (39, 49, 50). Mice used for experiments were of a pure C57BL/6J background, all male. Animals were sacrificed, and tissues were recovered and conserved at -80°C. All methods employed in this study were in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publications No. 85-23, revised 1996) and with the ethical committee of IDIBELL and the Generalitat de Catalunya.

### Treatment of mice

$\alpha$ -Lipoic acid (LA) (0.5% w/w) was mixed into AIN-76A chow from Dyets (Bethlehem, PA). N-acetylcysteine (1%) was dissolved in water (pH 3.5) (38).

Eight-month-old animals were randomly assigned to one of the following dietary groups for 4 months. Group I (Wt): Wt mice ( $n=8$ ) received only normal AIN-76A chow, Group II (*Abcd1*<sup>-</sup>): *Abcd1*<sup>-</sup> mice ( $n=8$ ) received only normal AIN-76A chow, and Group III (*Abcd1*<sup>-</sup> + Antx [Antioxidant]) *Abcd1*<sup>-</sup> mice ( $n=6$ ) were treated with chow containing LA and with NAC in drinking water (38).

### Cell culture and treatments

Control from healthy donors ( $n=5$ ) and X-ALD human fibroblasts ( $n=5$ ) were obtained after informed consent at the Bellvitge University Hospital. Cells were treated in medium

containing FCS (10%) at 37°C in humidified 95% air/5% CO<sub>2</sub>. After the growing period, the medium was changed to serum-free medium supplemented with 100  $\mu$ M BSA (free fatty acid)-bound fatty acid for 7 days at a 2:1 C26:0 fatty acid/BSA ratio. Untreated cells received an amount of BSA equal to that grown with the BSA-fatty acid complex. No significant changes in morphology were observed during incubation in serum-free medium (Supplementary Fig. S4). Unless otherwise stated, experiments were carried out with cells at 95% of confluence. Lines were used on passages 12–18.

### Monodimensional electrophoresis and western blotting

Tissues were removed from euthanized mice and flash-frozen on liquid nitrogen. Frozen tissues and human fibroblasts samples were homogenized in RIPA buffer using a motor-driven grinder (Sigma-Aldrich) and then sonicated for 2 min at 4°C in an Ultrasonic processor UP50H (Hielscher-Ultrasound Technology). Ten to 100  $\mu$ g were loaded on to each lane of 10% polyacrylamide gels for 60 min at 120 mV. Resolved proteins were transferred onto nitrocellulose membrane. Proteins were detected with ECL western blotting analysis system followed by exposure to CL-XPosure Film (Thermo Scientific). Autoradiographs were scanned and quantified using GS800 Densitometer (Bio-Rad).

### Two-dimensional electrophoresis and western blotting

Spinal cord and human fibroblast samples were homogenized in a lysis buffer (180 mM KCl, 5 mM MOPS, 2 mM EDTA, 1  $\mu$ M butylated hydroxytoluene, and protease inhibitor cocktail [Roche Diagnostics GmbH]) using a motor-driven grinder, sonicated for 2 min at 4°C in a Ultrasonic processor UP50H, and then centrifuged for 5 min at 1000 g. Afterward, the supernatant was collected and a new centrifugation (5 min, 1000 g) was carried out. After quantification, 1 mg of protein was precipitated with 20% TCA, and the pellet was resuspended in 200  $\mu$ l of a denaturing buffer (9 M urea, 4% CHAPS). Proteins were newly quantified, and 100–200  $\mu$ g of proteins was dissolved in IEF (Isoelectric focusing) buffer (9 M urea, 4% CHAPS, 1% bromophenol blue, 50 mM DTT, and 0.5% ampholites (pH 3–11NL (GE Healthcare Bio-Sciences AB) up to 340  $\mu$ l. This solution was applied overnight to 3–11 NL 18 cm IPG strips (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Isoelectric focusing migration was performed as follows: 250 V for 5h, followed by a linear gradient to 60,000 V, and then 250 V for 1 h in a Bio-Rad system. Strips were derivatized in a solution of 0.2% DNPH in HCl 2 N for 10 min and then equilibrated in 2 M TrisHCl-30% glycerol buffer for 15 min. For the last two steps of re-equilibration, strips were first incubated in a buffer containing 6 M urea, 2% SDS, 20% glycerol, 0.13 M DTT, and 0.375 M TrisHCl pH 8.8 for 10 min and then in the same buffer containing 2.5% iodoacetamide for 10 min. The equilibrated strips were loaded in a 10% SDS-PAGE gel (20  $\times$  20 cm) and run at 250 V for 4 h at RT. For oxyblot, proteins were transferred on to nitrocellulose membranes and then detected with ECL western blotting analysis system followed by exposure to CL-XPosure Film (Thermo Scientific). This method is based on the formation of a hydrazone (DNP) resulting from the reaction of protein-bound carbonyl and 2,4-dinitrophenylhydrazine. An antibody against DNP is used to detect carbonylated proteins (54). Thereby, we performed two-dimensional (2D) gels in

parallel. The first gel was silver stained to detect whole proteins, and the second one was transferred on to nitrocellulose membrane to detect oxidized protein. However, before the second electrophoresis migration and the transfer on to nitrocellulose membrane, samples were derivatized on to the strips with 2,4-dinitrophenylhydrazine (DNPH) after the first isoelectric focusing migration (Fig. 1A). Then, differentially oxidized cut spots were digested with trypsin (DigestPro MS), and peptides were analyzed by MS. Peptide Mass Fingerprinting database was used to identify proteins from a spectrum generated by MS (Supplementary Table S1). For silver staining, 2D gels were fixed for 30 min in a solution containing 30% ethanol and 70% glacial acetic acid. The fixing solution was replaced with sensitizing solution consisting of 30% ethanol, 0.2% w/v sodium thiosulphate, and 6.8% w/v sodium acetate. After 30 min, the sensitizing solution was removed, and the gels were washed thrice with distilled water for 5 min. The gels were stained with a silver solution containing 2.5 g/l of silver nitrate for 20 min and then washed twice with distilled water for 1 min. The gels were put in a solution of sodium carbonate 2.5% w/v. To arrest the developing process, solution was removed and the reaction was stopped with a solution containing EDTA-Na<sub>2</sub> 1.26% w/v.

Fold difference was statistically compared among the five independent experiments. Proteins for further investigation were selected on the basis of their higher oxidation values when comparing *Wt versus Abcd1*<sup>-</sup> (Supplementary Fig. S5).

#### Protein identification

Proteins were identified in the Proteomic Unit of Institut de Recerca Vall d'Hebron (Barcelona) (Supplementary Table S1). Detailed methodology is described in the Supplementary Methods.

#### Metabolomics

Metabolites were extracted from homogenate tissues with methanol as previously described (67). Briefly, 60  $\mu$ l of cold methanol was added to 20  $\mu$ l of homogenate (containing 1.85  $\mu$ g protein), vortexed for 1 min, and incubated at -20°C for 1 h to precipitate proteins. Samples were centrifuged for 3 min at 12,000 g, and the supernatant was collected. The supernatant was dried in a SpeedVac and resuspended in 50  $\mu$ l of water. The sample was filtered in an eppendorf UltraFree 5 kDa filter. Four microliters of extracted sample was applied to a reverse-phase column (C18 Luna 3n pfp(2) 100A 150\*2 mm, Phenomenex). The flow rate was 200  $\mu$ l/min with solvent A composed of water containing 0.1% formic acid for positive ionization or 0.1% acetic acid for negative ionization, and solvent B composed of 95% acetonitrile and 5% water containing corresponding counterions. The gradient consisted of a gradient of solvent B from 5% to 100% in 20 min, held at 100% solvent B for 5 min, and re-equilibrated at 5% solvent B for 6 min. Data were collected in positive electrospray mode in a QTOF (Agilent) operated in full-scan mode at 100–3000 *m/z*. The capillary voltage was 3500 V with a scan rate of 1 scan/s. N<sub>2</sub> was used as a gas nebulizer (flow was 5 l/min and temperature was 350°C). We used the MassHunter Data Analysis Software (Agilent) to collect the results and the MassHunter Qualitative Analysis (Agilent) to perform the integration and metabolite quantitation. The identity of metabolites was confirmed by identity of mass, isotopic distribution, and coelution with authentic standards. The *m/z* values used for quantifica-

tion were *m/z* 394.9781 [2M+Na]<sup>+</sup> for 2 (or 3) phosphoglycerate, *m/z* 176.0546 [2M+NH<sub>4</sub><sup>+</sup>-H<sub>2</sub>O]<sup>+</sup> for pyruvate, *m/z* 229.0133 [M+CH<sub>3</sub>COO]<sup>-</sup> for DHAP/GA3P, *m/z* 193.0343 [M+H]<sup>+</sup> for citrate, *m/z* 292.0662 [2M+NH<sub>4</sub><sup>+</sup> + [-H<sub>2</sub>O] for  $\alpha$ -ketoglutarate, *m/z* 338.9888 [M-H]<sup>-</sup> for fructose-1,6-biphosphate, *m/z* 115.0038 [M-H]<sup>-</sup> for fumarate, *m/z* 133.0136 for malate, *m/z* 112.5880 [M-H]<sup>-</sup> for oxalacetate, and *m/z* 179.0547 [2M-H]<sup>-</sup> for lactate. In all cases,  $\Delta$  between calculated molecular weight (M.W.) and detected masses was lower than 0.001 Da. The identity of all metabolites was confirmed by identical chromatographic and mass spectrometric properties (molecular weight and isotopic distribution) of the quantified metabolites in comparison with authentic standards.

#### ATP levels

Mice were sacrificed by cervical dislocation, and spinal cords were immediately frozen in liquid nitrogen and stored at -80°C. ATP was extracted with cold perchloric acid (10%) from 10 mg of spinal cord, neutralized with KOH, and centrifuged (34). Then, ATP concentrations were quantified in triplicate per animal using the ATPlite 1 step (PerkinElmer) according to the manufacturer's protocol. Data were normalized to mg of proteins. All assays were performed in triplicate.

#### NAD-NADH and NADP-NADPH determinations

NAD<sup>+</sup>, NADH and NADP<sup>+</sup>, NADPH were, respectively, quantified by the NAD and NADP cycling assay. Detailed methodology is described in the Supplementary Methods.

#### Q-TOF based GSH analyses

Spinal cord samples were homogenate with a buffer containing 200 mM methane sulphonic acid with 5 mM DTPAC. Detailed methodology is described in Supplementary Methods.

#### Respiratory chain activity

We quantified the activities of complex I plus complex III, complex II plus complex III, complex IV, and Citrate synthase in the spinal cord samples from 12 month-old *Abcd1*<sup>-</sup> mice. Detailed methodology is described in Supplementary Methods.

#### Pyruvate kinase activity

Pyruvate kinase activity was determined by a spectrophotometrical method as previously described (26). 15  $\mu$ g of mitochondria-free supernatant was added to a 0.2 ml of reaction buffer (50 mM TrisHCl pH 7.4, 100 mM KCl, 20 mM MgCl<sub>2</sub>, 0.3 mM NADH, 4 mM ADP, 1 mM phosphoenolpyruvate (PEP), and 5 units/ml of lactate dehydrogenase [LDH]). NADH was spectrophotometrically recorded after 6 min at 340 nm in a microplate spectrophotometer (PowerWave Microplate Spectrophotometer, BioTek). All assays were performed in triplicate at room temperature. Results were expressed as units ( $\mu$ mol/min) per mg tissue.

#### RNA extraction and quantitative real-time PCR

Total RNA was extracted using RNeasy Kit (Qiagen), and Q-PCR experiments were performed according to manufacturer's instructions (LightCycler, Roche Diagnostics) as previously described (21). PCR were carried out with *36b4* (also called *Rpl0*) used as a standard gene. The nucleotide se-

quences of primers are available (Supplementary Table S2). Data are given as mean  $\pm$  SD.

### Statistical analysis

Data are given as mean  $\pm$  SD. Significant differences were determined by one-way ANOVA followed by Tukey HSD *post hoc* test after verifying normality ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ) or Student's *t* test ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ). Statistical analyses were performed using SPSS 12.0 program.

### Acknowledgments

This study was supported by grants from the European Commission [FP7-241622], the European Leukodystrophy Association [ELA2009-036C5; ELA2008-040C4], the Spanish Institute for Health Carlos III [FIS PI080991 and FIS PI051118], and the Autonomous Government of Catalonia [2009SGR85] to A.P. The CIBER de Enfermedades Raras is an initiative of the ISCIII. The study was developed under the COST action BM0604 [to A.P.]. J. L-E. was a fellow of the Department of Education, Universities, and Research of the Basque Regional Government [BFI07.126]. S.F. was a fellow of the European Leukodystrophy Association [ELA 2007-018F4], and J.G. was a fellow of the IDIBELL program of PhD-student fellowships.

Work carried out at the Department of Experimental Medicine was supported in part by R+D grants from the Spanish Ministry of Science and Innovation [AGL2006-12433 and BFU2009-11879/BFI], the Spanish Ministry of Health [RD06/0013/0012 and PI081843], the Autonomous Government of Catalonia [2009SGR735], and COST B35 Action of the European Union.

The authors are indebted to Professor Isabel Fabregat for scientific discussion.

### Author Disclosure Statement

No competing financial interests exist.

### References

- Aliev G, Liu J, Shenk JC, Fischbach K, Pacheco GJ, Chen SG, Obrenovich ME, Ward WF, Richardson AG, Smith MA, Gasimov E, Perry G, and Ames BN. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. *J Cell Mol Med* 13: 320–333, 2009.
- Ambrus A, Tretter L, and Adam-Vizi V. Inhibition of the alpha-ketoglutarate dehydrogenase-mediated reactive oxygen species generation by lipoic acid. *J Neurochem* 109 Suppl 1: 222–229, 2009.
- Arivazhagan P and Panneerselvam C. Effect of DL-alpha-lipoic acid on neural antioxidants in aged rats. *Pharmacol Res* 42: 219–222, 2000.
- Bagh MB, Thakurta IG, Biswas M, Behera P, and Chakrabarti S. Age-related oxidative decline of mitochondrial functions in rat brain is prevented by long term oral antioxidant supplementation. *Biogerontology* 12: 119–131, 2011.
- Baumgart E, Vanhorebeek I, Grabenbauer M, Borgers M, Declercq PE, Fahimi HD, and Baes M. Mitochondrial alterations caused by defective peroxisomal biogenesis in a mouse model for Zellweger syndrome (PEX5 knockout mouse). *Am J Pathol* 159: 1477–1494, 2001.
- Bisaglia M, Soriano ME, Arduini I, Mammi S, and Bubacco L. Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. *Biochim Biophys Acta* 1802: 699–706, 2010.
- Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, and Beal MF. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. *Neurobiol Dis* 22: 599–610, 2006.
- Bulteau AL, Ikeda-Saito M, and Szweda LI. Redox-dependent modulation of aconitase activity in intact mitochondria. *Biochemistry* 42: 14846–14855, 2003.
- Butterfield DA and Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. *J Neurochem* 111: 915–933, 2009.
- Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, and Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. *Neurobiol Dis* 22: 223–232, 2006.
- Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, and Mattson MP. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. *Antioxid Redox Signal* 13: 1763–1811, 2010.
- Calabrese V, Cornelius C, Maiolino L, Luca M, Chiamonte R, Toscano MA, and Serra A. Oxidative stress, redox homeostasis and cellular stress response in Meniere's disease: role of vitagenes. *Neurochem Res* 35: 2208–2217, 2010.
- Chan A, Paskavitz J, Remington R, Rasmussen S, and Shea TB. Efficacy of a vitamin/nutritional formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. *Am J Alzheimers Dis Other Demen* 23: 571–585, 2008.
- Di Domenico F, Perluigi M, Butterfield DA, Cornelius C, and Calabrese V. Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. *Neurochem Res* 35: 2184–2192, 2010.
- Dodd S, Dean O, Copolov DL, Malhi GS, and Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. *Expert Opin Biol Ther* 8: 1955–1962, 2008.
- Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. *J Bioenerg Biomembr* 41: 425–431, 2009.
- Ferrer I, Aubourg P, and Pujol A. General aspects and neuropathology of X-linked adrenoleukodystrophy. *Brain Pathol* 20: 817–830, 2010.
- Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V, Callyot N, Mooyer P, Selhorst J, Vreken P, Wanders RJ, Mandel JL, and Pujol A. Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. *Hum Mol Genet* 14: 3565–3577, 2005.
- Formentini L, Martinez-Reyes I, and Cuezva JM. The mitochondrial bioenergetic capacity of carcinomas. *IUBMB Life* 62: 554–560, 2010.
- Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, Jove M, Kemp S, Villarroya F, Ferrer I, Pamplona R, Portero-Otin M, and Pujol A. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. *Hum Mol Genet* 17: 1762–1773, 2008.
- Fourcade S, Ruiz M, Camps C, Schluter A, Houten SM, Mooyer PA, Pampols T, Dacremont G, Wanders RJ, Giros M, and Pujol A. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. *Am J Physiol Endocrinol Metab* 296: E211–E221, 2009.



22. Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A, Portero-Otin M, Dacremont G, Cartier N, Wanders R, Kemp S, Mandel JL, Wirth B, Pamplona R, Aubourg P, and Pujol A. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. *Hum Mol Genet* 19: 2005–2014, 2010.
23. Gibson GE, Starkov A, Blass JP, Ratan RR, and Beal MF. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. *Biochim Biophys Acta* 1802: 122–134, 2010.
24. Gilg AG, Singh AK, and Singh I. Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. *J Neuropathol Exp Neurol* 59: 1063–1069, 2000.
25. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken HH, Becker D, Voos W, Leuner K, Muller WE, Kudin AP, Kunz WS, Zimmermann A, Roeper J, Wenzel D, Jendrach M, Garcia-Arencibia M, Fernandez-Ruiz J, Huber L, Rohrer H, Barrera M, Reichert AS, Rub U, Chen A, Nussbaum RL, and Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. *PLoS One* 4: e5777, 2009.
26. Gutmann I and Bernt E. *Methods of Enzymatic Analysis*. New-York: Verlag Chemie Weinheim, Academic Press, Inc., 1974, pp. 774–777.
27. Hamm-Kunzelmann B, Schafer D, Weigert C, and Brand K. Redox-regulated expression of glycolytic enzymes in resting and proliferating rat thymocytes. *FEBS Lett* 403: 87–90, 1997.
28. Harvey BH, Joubert C, du Preez JL, and Berk M. Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. *Neurochem Res* 33: 508–517, 2008.
29. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, and Muller WE. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. *Neurobiol Aging* 30: 1574–1586, 2009.
30. Herrero-Mendez A, Almeida A, Fernandez E, Maestre C, Moncada S, and Bolanos JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. *Nat Cell Biol* 11: 747–752, 2009.
31. Hirrlinger J and Dringen R. The cytosolic redox state of astrocytes: maintenance, regulation and functional implications for metabolite trafficking. *Brain Res Rev* 63: 177–188, 2010.
32. Humphries KM and Szwedda LI. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. *Biochemistry* 37: 15835–15841, 1998.
33. Janero DR, Burghardt C, and Feldman D. Amphiphile-induced heart muscle-cell (myocyte) injury: effects of intracellular fatty acid overload. *J Cell Physiol* 137: 1–13, 1988.
34. Khan HA. Bioluminometric assay of ATP in mouse brain: determinant factors for enhanced test sensitivity. *J Biosci* 28: 379–382, 2003.
35. Lacraz G, Figeac F, Movassat J, Kassis N, Coulaud J, Galinier A, Leloup C, Bailbe D, Homo-Delarche F, and Portha B. Diabetic beta-cells can achieve self-protection against oxidative stress through an adaptive up-regulation of their antioxidant defenses. *PLoS One* 4: e6500, 2009.
36. Leuner K, Hauptmann S, Abdel-Kader R, Scherping I, Keil U, Strosznajder JB, Eckert A, and Muller WE. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? *Antioxid Redox Signal* 9: 1659–1675, 2007.
37. Lin MT and Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature* 443: 787–795, 2006.
38. López-Erauskin J, Fourcade S, Galino J, Ruiz M, Schlüter A, Naudi A, Jove M, Portero-Otin M, Pamplona R, Ferrer I, and Pujol A. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. *Ann Neurol* (in press); DOI: 10.1002/ana.22363, 2011.
39. Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, and Smith KD. A mouse model for X-linked adrenoleukodystrophy. *Proc Natl Acad Sci USA* 94: 9366–9371, 1997.
40. Martinez A, Portero-Otin M, Pamplona R, and Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. *Brain Pathol* 20: 281–297, 2010.
41. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, and Perry G. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. *J Alzheimers Dis* 12: 195–206, 2007.
42. Moser H, Smith KD, Watkins PA, Powers J, and Moser AB. X-linked adrenoleukodystrophy. In: *The Metabolic and Molecular Bases of Inherited Disease*, edited by Scriver C. New-York: McGraw-Hill, 2001, pp. 3257–3301.
43. Nulton-Persson AC and Szwedda LI. Modulation of mitochondrial function by hydrogen peroxide. *J Biol Chem* 276: 23357–23361, 2001.
44. Packer L, Tritschler HJ, and Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. *Free Radic Biol Med* 22: 359–378, 1997.
45. Pamplona R and Barja G. Highly resistant macromolecular components and low rate of generation of endogenous damage: two key traits of longevity. *Ageing Res Rev* 6: 189–210, 2007.
46. Parihar MS and Brewer GJ. Mitochondrial failure in Alzheimer disease. *Am J Physiol Cell Physiol* 292: C8–C23, 2007.
47. Perluigi M, Di Domenico F, Giorgi A, Schinina ME, Coccia R, Cini C, Bellia F, Cambria MT, Cornelius C, Butterfield DA, and Calabrese V. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. *J Neurosci Res* 88: 3498–3507, 2010.
48. Phillips SA and Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. *Eur J Biochem* 212: 101–105, 1993.
49. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pampols T, Giros M, and Mandel JL. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. *Hum Mol Genet* 13: 2997–3006, 2004.
50. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, and Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. *Hum Mol Genet* 11: 499–505, 2002.
51. Remington R, Chan A, Paskavitz J, and Shea TB. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. *Am J Alzheimers Dis Other Dement* 24: 27–33, 2009.
52. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, and Eckert A. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. *Proc Natl Acad Sci USA* 106: 20057–20062, 2009.
53. Rinholm JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, and Attwell D. Regulation of oligodendrocyte

- development and myelination by glucose and lactate. *J Neurosci* 31: 538–548, 2011.
54. Robinson CE, Keshavarzian A, Pasco DS, Frommel TO, Winship DH, and Holmes EW. Determination of protein carbonyl groups by immunoblotting. *Anal Biochem* 266: 48–57, 1999.
  55. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, and Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. *Muscle Nerve* 35: 235–242, 2007.
  56. Shacter E. Quantification and significance of protein oxidation in biological samples. *Drug Metab Rev* 32: 307–326, 2000.
  57. Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, Lamanna JC, and Aliev G. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. *J Neurol Sci* 283: 199–206, 2009.
  58. Singh I and Pujol A. Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. *Brain Pathol* 20: 838–844, 2010.
  59. Sowell RA, Owen JB, and Butterfield DA. Proteomics in animal models of Alzheimer's and Parkinson's diseases. *Ageing Res Rev* 8: 1–17, 2009.
  60. Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, and Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. *J Neurosci* 24: 7779–7788, 2004.
  61. Stern N, Hochman A, Zemach N, Weizman N, Hammel I, Shiloh Y, Rotman G, and Barzilai A. Accumulation of DNA damage and reduced levels of nicotine adenine dinucleotide in the brains of Atm-deficient mice. *J Biol Chem* 277: 602–608, 2002.
  62. Tan JS, Wang JJ, Flood V, Rohtchina E, Smith W, and Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. *Ophthalmology* 115: 334–341, 2008.
  63. Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. *Adv Drug Deliv Rev* 60: 1561–1567, 2008.
  64. Tretter L and Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. *J Neurosci* 20: 8972–8979, 2000.
  65. Tretter L and Adam-Vizi V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. *Philos Trans R Soc Lond B Biol Sci* 360: 2335–2345, 2005.
  66. van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W, Waterham HR, and Wanders RJ. The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. *FASEB J* 22: 4201–4208, 2008.
  67. Wikoff WR, Pendyala G, Siuzdak G, and Fox HS. Metabonomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. *J Clin Invest* 118: 2661–2669, 2008.
  68. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, and Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 106: 14670–14675, 2009.
  69. Ying W. NAD<sup>+</sup>/NADH and NADP<sup>+</sup>/NADPH in cellular functions and cell death: regulation and biological consequences. *Antioxid Redox Signal* 10: 179–206, 2008.
  70. Zhao Y, Seefeldt T, Chen W, Wang X, Matthees D, Hu Y, and Guan X. Effects of glutathione reductase inhibition on cellular thiol redox state and related systems. *Arch Biochem Biophys* 485: 56–62, 2009.

Address correspondence to:

Prof. Aurora Pujol  
 Neurometabolic Diseases Laboratory  
 Institut d'Investigació Biomèdica de Bellvitge  
 Hospital Duran i Reynalds  
 Hospitalet de Llobregat  
 Gran Via 199  
 Barcelona 08907  
 Spain

E-mail: apujol@idibell.cat

Date of first submission to ARS Central, December 31, 2010; date of final revised submission, March 28, 2011; date of acceptance, March 31, 2011.

#### Abbreviations Used

AASA = amino adipic semialdehyde  
 ACO2 = mitochondrial aconitase  
 AD = Alzheimer's disease  
 ADH = alcohol dehydrogenase  
 ALDOA = aldolase A  
 ALS = amyotrophic lateral sclerosis  
 Antx = antioxidant  
 CEL = carboxyethyl-lysine  
 CML = carboxymethyl-lysine  
 DHAP = dihydroxyacetone phosphate  
 DLD = dihydrolipoamide dehydrogenase  
 DNP = 2,4-dinitrophenylhydrazine  
 DNPH = 2,4-dinitrophenylhydrazine  
 DTPAC = diethylenetriaminepentaacetic acid  
 EOAD = early onset Alzheimer disease  
 G6P = glucose 6-phosphate  
 G6PDH = glucose 6-phosphate dehydrogenase  
 GA3P = glyceraldehyde 3-phosphate  
 GSA = glutamic semialdehyde  
 GSH = reduced glutathione  
 HD = Huntington's disease  
 IEF = isoelectric focusing  
 iPD = infantile Parkinson disease  
 KGDHC =  $\alpha$ -ketoglutarate dehydrogenase complex  
 LA =  $\alpha$ -lipoic acid  
 LDH = lactate dehydrogenase  
 MCI = amnesic mild cognitive impairment  
 MGO = methylglyoxal  
 MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
 MW = molecular weight  
 m/z = mass-to-charge ratio  
 NAC = N-acetylcysteine  
 OAA = oxaloacetate  
 PD = Parkinson's disease  
 PDHC = pyruvate dehydrogenase complex  
 PEP = phosphoenolpyruvate  
 PES = phenazine ethosulphate  
 PGK1 = phosphoglycerate kinase  
 PKM2 = pyruvate kinase  
 PSP = progressive supranuclear palsy  
 ROS = reactive oxygen species  
 TCA = tricarboxylic acid  
 VLCFA = very long-chain fatty acids  
 X-ALD = X-linked adrenoleukodystrophy

